News NEWS PRESS RELEASES EVENT ATTENDENCES PEER-REVIEWED PUBLICATIONS NEWS SilkTech completes patient enrollment for their Phase 2B clinical trial the use of SDP-4 in treating the signs and symptoms of Dry Eye DiseaseJuly 15, 2019Press Release: SilkTech Biopharmaceuticals Completes Enrollment of Phase 2B Clinical Trial of SDP-4 for the Treatment of the Signs and Symptoms of Dry Eye DiseaseJuly 15, 2019SilkTech Biopharmaceuticals will be attending OIS@ASCRSApril 26, 2019SilkTech’s head of R&D, Dr. David Infanger, will be presenting new research at ARVO 2019 in Vancouver, BC.April 24, 2019SilkTech announces IND clearance from FDA for the SDP-4 eye drop and initiates a Phase 2B clinical trial for patients with Dry Eye Disease.April 17, 2019US Army awards $537,000 to SilkTech to support clinical development of SDP-4 eye drop productApril 1, 2019SilkTech forms Medical Advisory Board with world-leading clinicians in both Ophthalmology and Optometry.February 18, 2019SilkTech Biopharmaceuticals to present at the inaugural OIS@SECO meeting in New Orleans, LA.January 28, 2019Defense Health Agency (DHA) awards $500,000 to SilkTech to support SDP-4 eye drop analytical test method development work.November 13, 2018SilkTech’s CEO, Dr. Brian Lawrence, to present at the 10th annual OIS@AAO conference in Chicago, IL.October 23, 2018SilkTech to attend OIS@AAO 2018 conference in Chicago, IL.April 2, 2018SilkTech issued patent from USPTO for the use of their novel SDP material in ophthalmic formulations.March 6, 2018Collaborative in vivo corneal research on Silk-Derived Protein (SDP) published with Weill Cornell Medical College, University of Illinois – Chicago, and SilkTech in the scientific journal PLoS ONE.November 20, 2017World recognized leaders in Ophthalmology, Dr. Emmett Cunningham Jr. and Dr. Paul Karpecki, have joined SilkTech’s Board of Directors.November 16, 2017Skyview Capital makes significant investment in SilkTech with Series A venture round.November 8, 2017SilkTech to attend OIS@AAO 2017 conference in New Orleans, LA.November 6, 2017US Army awards $1,000,000 to SilkTech to support development of the company’s flagship SDP-4 biologic drug candidate.September 18, 2017Research on studying Silk-Derived Protein (SDP) on in vitro corneal models co-published with Weill Cornell Medical College, University of Illinois – Chicago, and SilkTech in the leading vision research journal IOVS.March 1, 2017US Army awards $150,000 to SilkTech to support R&D efforts into exploring the potential ocular healing attributes of the company’s Silk-Derived Protein (SDP) material.December 22, 2016SilkTech issued first patent from USPTO for their novel Silk-Derived Protein material.July 19, 2016 Search Submit Clear Subscribe to Blog via Email Enter your email address to subscribe to this blog and receive notifications of new posts by email. Email Address Subscribe
SilkTech completes patient enrollment for their Phase 2B clinical trial the use of SDP-4 in treating the signs and symptoms of Dry Eye DiseaseJuly 15, 2019
Press Release: SilkTech Biopharmaceuticals Completes Enrollment of Phase 2B Clinical Trial of SDP-4 for the Treatment of the Signs and Symptoms of Dry Eye DiseaseJuly 15, 2019
SilkTech’s head of R&D, Dr. David Infanger, will be presenting new research at ARVO 2019 in Vancouver, BC.April 24, 2019
SilkTech announces IND clearance from FDA for the SDP-4 eye drop and initiates a Phase 2B clinical trial for patients with Dry Eye Disease.April 17, 2019
US Army awards $537,000 to SilkTech to support clinical development of SDP-4 eye drop productApril 1, 2019
SilkTech forms Medical Advisory Board with world-leading clinicians in both Ophthalmology and Optometry.February 18, 2019
SilkTech Biopharmaceuticals to present at the inaugural OIS@SECO meeting in New Orleans, LA.January 28, 2019
Defense Health Agency (DHA) awards $500,000 to SilkTech to support SDP-4 eye drop analytical test method development work.November 13, 2018
SilkTech’s CEO, Dr. Brian Lawrence, to present at the 10th annual OIS@AAO conference in Chicago, IL.October 23, 2018
SilkTech issued patent from USPTO for the use of their novel SDP material in ophthalmic formulations.March 6, 2018
Collaborative in vivo corneal research on Silk-Derived Protein (SDP) published with Weill Cornell Medical College, University of Illinois – Chicago, and SilkTech in the scientific journal PLoS ONE.November 20, 2017
World recognized leaders in Ophthalmology, Dr. Emmett Cunningham Jr. and Dr. Paul Karpecki, have joined SilkTech’s Board of Directors.November 16, 2017
Skyview Capital makes significant investment in SilkTech with Series A venture round.November 8, 2017
US Army awards $1,000,000 to SilkTech to support development of the company’s flagship SDP-4 biologic drug candidate.September 18, 2017
Research on studying Silk-Derived Protein (SDP) on in vitro corneal models co-published with Weill Cornell Medical College, University of Illinois – Chicago, and SilkTech in the leading vision research journal IOVS.March 1, 2017
US Army awards $150,000 to SilkTech to support R&D efforts into exploring the potential ocular healing attributes of the company’s Silk-Derived Protein (SDP) material.December 22, 2016
